Low Dose Tadalafil for Treatment of Female OAB Syndrome: Short Term Follow up.
NCT ID: NCT04500860
Last Updated: 2022-08-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
90 participants
INTERVENTIONAL
2020-12-01
2022-07-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Solifenacin Plus Tadalafil vs Solifenacin Alone for Overactive Bladder in Females
NCT07312955
Management of OAB in Female Patients .
NCT06184334
A Therapeutic Exploratory Clinical Study of DA-8010 in Patients With Overactive Bladder
NCT03566134
Studies of Psychiatric Predisposing Factors, Treatment-related Cardiovascular Effects, and Prognostic Factors Associated With Antimuscarinic Drug (Tolterodine) for Female Overactive Bladder Syndrome
NCT01503580
Clinical Study to Assess the Efficacy and Safety of THVD-201 in Patients With OAB
NCT02485067
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group A Tadalafil 5 mg
30 patients subjected to Daily dose of tadalafil 5mg
Low dose tadalafil 5 mg
Efficacy of daily low dose tadalafil 5mg for treatment of female overactive bladder syndrome or urgency with or without urgency urinary incontinence
Group B Tolterodine
30 patients subjected to tolterodine 4 mg daily
Tolterodine 4 Mg Oral Capsule, Extended Release
To compare efficacy of low dose tadalafil 5 mg to tolterodine 4 mg extended release in treatment of female overactive bladder
Group C placebo
30 patients subjected to placebo daily
Placebo
Placebo drugs
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Low dose tadalafil 5 mg
Efficacy of daily low dose tadalafil 5mg for treatment of female overactive bladder syndrome or urgency with or without urgency urinary incontinence
Tolterodine 4 Mg Oral Capsule, Extended Release
To compare efficacy of low dose tadalafil 5 mg to tolterodine 4 mg extended release in treatment of female overactive bladder
Placebo
Placebo drugs
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* neurologic abnormality
* Pure Stress urinary incontinence
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Kasr El Aini Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Samer Morsy
Urology lecturer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Samer Morsy
Cairo, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Cairo University
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.